Myriad Genetics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Myriad Genetics (MYGN)

On May 5, 2026, Myriad Genetics management reaffirmed full-year revenue of $860-$880 million. Just three months later, the Company cut guidance to $770-$790 million and adjusted EBITDA guidance was suspended -- and MYGN shareholders absorbed the loss. NEW YORK, Aug. 3, 2026 /PRNewswire/...